Roivant swings to Q3 loss as revenue drops

Roivant Sciences

06/02/2026 12:12

Overview

Biopharmaceutical firm's Q3 revenue drops to $2 mln from $9 mln yr-ago

Posts Q4 net loss vs profit in year-ago quarter

Roivant reported $4.5 bln in cash and marketable securities as of Dec 31, 2025

Outlook

Roivant plans Phase 3 study for brepocitinib in cutaneous sarcoidosis starting in 2026

Company expects topline data from brepocitinib NIU trial in second half of 2026

Roivant actively exploring additional indications for brepocitinib

Result Drivers

R&D EXPENSES - Increase in R&D expenses driven by program-specific costs and share-based compensation

STRONG CASH POSITION - Reported $4.5 bln in cash and marketable securities as of Dec 31, 2025

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
$2 mln
Q3 EPS
-$0.38
Q3 Net Income
-$313.70 mln
Q3 Income From Operations
Miss
-$339.15 mln
-$306.38 mln (6 Analysts)
Q3 Operating Expenses
$341.15 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Roivant Sciences Ltd is $26.00, about 23% above its February 5 closing price of $21.14

Press Release: ID:nGNX547nb2

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)